8/2/2023 0 Comments Intacept 25 mg injectionNo dose adjustment is required for elderly and or patient with renal and hepatic impairment. With intermittent use, treatment cycles subsequent to the initial cycle should use a dose of 50 mg once weekly. Treatment should be discontinued in patients who show no response after 12 weeks. Adult patients may be treated intermittent or continuously based on physician judgment and individual patient needs. Higher responses may be achieved from initial treatment with a dose of 50 mg twice weekly for up to 12 weeks, followed, if necessary, by a dose of 50 mg once weekly or 25 mg twice weekly. Plaque psoriasis: The dose of etanercept is 50 mg syringe once weekly (as one subcutaneous injection using a 50 mg syringe or as two 25 mg injections given at approximately the same time) or 25 mg twice weekly (72 to 96 hours apart) as a subcutaneous injection. 25 mg once weekly gives a slower response and may be less effective. ![]() Methotrexate, glucocorticoids, salicylates, nonsteroidal anti- inflammatory drugs (NSAIDs), or analgesics may be continued during treatment with Intacept in adults. Rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: Patients aged 18 years or older- 50 mg Intacept per week administered either once weekly (as one subcutaneous injection using a 50 mg syringe or as two 25 mg injections given at the same time) or 25 mg Intacept twice weekly (72 to 96 hours apart) as a subcutaneous injection. Intacept is also used to associated treatment for these conditions: Ankylosing Spondylitis (AS), Graft Versus Host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Stevens-Johnson Syndrome Pediatric patients with Plaque Psoriasis (PsO): Intacept is used for the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years, who are inadequately controlled by or are intolerant to systemic therapies or phototherapies. Adults with Plaque Psoriasis (PsO): Intacept is used for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. Adults with Ankylosing Spondylitis (AS): Intaceptis used for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). Intacept can be used in combination with methotrexate (MTX) in patients who do not respond adequately to MTX alone. Adults with Psoriatic Arthritis (PsA): Intacept is used for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Pediatric patients with Juvenile Idiopathic Arthritis(JIA): Intacept used for the treatment of polyarticular-course juvenile idiopathic arthritis (JIA) in children and adolescents from the age of 2 years when the response to one or more DMARDs has proven inadequate. Intacept can be initiated in combination with methotrexate (MTX) or used alone for the treatment of active rheumatoid arthritis (RA) in adults when one or more disease modifying antirheumatic drugs (DMARDs), including methotrexate (unless contraused), has proved inadequate. Such processes or molecules affected include the level of adhesion molecules expressed, as well as serum levels of cytokines and matrix metalloproteinases.Īdults with Rheumatoid Arthritis (RA): Intacept used for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Intacept binds specifically to tumor necrosis factor (TNF) and thereby modulates biological processes that are induced or regulated by TNF. It plays an important role in the inflammatory processes of rheumatoid arthritis (RA), polyarticular-course juvenile rheumatoid arthritis (JRA) and the resulting joint pathology. ![]() Elevated levels of TNF are found in the synovial fluid of RA patients. TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Intacept is a TNF alpha inhibitor that binds specifically to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors. It consists of 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons. Intacept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. This is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Intacept is a tumor necrosis factor (TNF) blocker.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |